Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples.

Details

Ressource 1Download: fmed-08-734901.pdf (1360.42 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_1D006817C045
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Delta-Like Protein 3 Expression in Paired Chemonaive and Chemorelapsed Small Cell Lung Cancer Samples.
Journal
Frontiers in medicine
Author(s)
Kuempers C., Jagomast T., Krupar R., Paulsen F.O., Heidel C., Ribbat-Idel J., Idel C., Märkl B., Anlauf M., Berezowska S., Tiemann M., Bösmüller H., Fend F., Kalsdorf B., Bohnet S., Dreyer E., Sailer V., Kirfel J., Perner S.
ISSN
2296-858X (Print)
ISSN-L
2296-858X
Publication state
Published
Issued date
2021
Peer-reviewed
Oui
Volume
8
Pages
734901
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate directed against Delta-like protein 3 (DLL3), is under development for patients with small cell lung cancer (SCLC). DLL3 is expressed on the majority of SCLC samples. Because SCLC is rarely biopsied in the course of disease, data regarding DLL3 expression in relapses is not available. The aim of this study was to investigate the expression of DLL3 in chemorelapsed (but untreated with Rova-T) SCLC samples and compare the results with chemonaive counterparts. Two evaluation methods to assess DLL3 expression were explored. Additionally, we assessed if DLL3 expression of chemorelapsed and/or chemonaive samples has prognostic impact and if it correlates with other clinicopathological data. The study included 30 paired SCLC samples, which were stained with an anti DLL3 antibody. DLL3 expression was assessed using tumor proportion score (TPS) and H-score and was categorized as DLL3 low (TPS < 50%, H-score ≤ 150) and DLL3 high (TPS ≥ 50%, H-score > 150). Expression data were correlated with clinicopathological characteristics. Kaplan-Meier curves were used to illustrate overall survival (OS) depending on DLL3 expression in chemonaive and chemorelapsed samples, respectively, and depending on dynamics of expression during course of therapy. DLL3 was expressed in 86.6% chemonaive and 80% chemorelapsed SCLC samples without significant differences between the two groups. However, the extent of expression varied in a substantial proportion of pairs (36.6% with TPS, 43.3% with H-score), defined as a shift from low to high or high to low expression. TPS and H-score provided comparable results. There were no profound correlations with clinicopathological data. Survival analysis revealed a trend toward a more favorable OS in DLL low-expressing chemonaive SCLC (p = 0.57) and, in turn, in DLL3 high-expressing chemorelapsed SCLC (p = 0.42) as well as in SCLC demonstrating a shift from low to high expression (p = 0.56) without being statistically significant. This is the first study to investigate DLL3 expression in a large cohort of rare paired chemonaive-chemorelapsed SCLC specimens. Comparative analysis revealed that DLL3 expression was not stable during the course of therapy, suggesting therapy-based alterations. Unlike in chemonaive samples, a high DLL3 expression in chemorelapsed samples indicated a trend for a more favorable prognosis. Our results highlight the importance to investigate DLL3 in latest chemorelapsed SCLC tumor tissue.
Keywords
chemonaive, chemorelapsed, delta-like protein 3, paired, small cell lung cancer
Pubmed
Web of science
Open Access
Yes
Create date
26/10/2021 14:54
Last modification date
11/11/2021 7:08
Usage data